The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

The first-quarter 2025 earnings season for the Medical sector is about to pick up pace this week. The sector mainly comprises ...

For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been ...

When it comes to Big Pharma, the likes of Novartis, Bristol Myers Squibb and AstraZeneca have Bluesky accounts — though none are posting.

No. 9 / 2025Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate ...

Results next week will likely provide a peek into how the world's top three oilfield services companies are navigating the uncertainty fueled by the on-again, off-again U.S. tariffs, as well as a ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.